The abstract is read at the publisher; the summary is JClub's.
VE800 plus nivolumab was well tolerated in advanced PD-1-refractory melanoma and PD-1-naive gastric/GEJ adenocarcinoma and MSS CRC, but did not improve response rates versus historic benchmarks.
- Why it matters: The study addresses variability and scalability limits of fecal microbiota transplantation, aiming to test a defined commensal consortium to enhance anti-PD-1 activity in advanced cancers.
- What they did: In this first-in-human, open-label phase 1 trial, VE800 (11 commensal strains from clonal cell banks) was given with nivolumab to assess safety and efficacy across three PD-1-defined cohorts.
- The result: Exploratory melanoma analyses linked VE800 strain engraftment to longer progression-free survival and higher peripheral immune activation, suggesting potential biomarkers despite no clear efficacy gain.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.